Cargando…
Synergistic effect of combination chemotherapy with praziquantel and DW-3-15 for Schistosoma japonicum in vitro and in vivo
BACKGROUND: Schistosomiasis is a debilitating and neglected tropical disease for which praziquantel (PZQ) remains the first-choice drug for treatment and control of the disease. In our previous studies, we found that the patented compound DW-3-15 (patent no. ZL201110142538.2) displayed significant a...
Autores principales: | Yang, Zi-Yin, Liu, Zi-Hao, Zhang, Ya-Nan, Li, Chen, Liu, Lei, Pu, Wen-Jie, Xie, Shi-Qi, Xu, Jing, Xia, Chao-Ming |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8549225/ https://www.ncbi.nlm.nih.gov/pubmed/34702326 http://dx.doi.org/10.1186/s13071-021-05065-x |
Ejemplares similares
-
In vitro and in vivo activities of DW-3-15, a commercial praziquantel derivative, against Schistosoma japonicum
por: Wang, Xiaoli, et al.
Publicado: (2019) -
New Insight into the Antifibrotic Effects of Praziquantel on Mice in Infection with Schistosoma japonicum
por: Liang, Yue-Jin, et al.
Publicado: (2011) -
Synthesis and SAR Studies of Praziquantel Derivatives with Activity against Schistosoma japonicum
por: Wang, Wen-Long, et al.
Publicado: (2013) -
In vivo efficiency of praziquantel treatment of single-sex Schistosoma japonicum aged three months old in mice
por: Wang, Ning, et al.
Publicado: (2022) -
Population Pharmacokinetics of Praziquantel in Pregnant and Lactating Filipino Women Infected with Schistosoma japonicum
por: Bustinduy, Amaya L., et al.
Publicado: (2020)